Why Climb Bio, Inc.’s (CLYM) Stock Is Down 5.55%
As of Friday, October 16, Climb Bio, Inc.’s CLYM share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Commentary & Analysis
Why Climb Bio, Inc.’s (CLYM) Stock Is Down 6.78%
As of Friday, October 16, Climb Bio, Inc.’s CLYM share price has dipped by 6.78%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Climb Bio, Inc.’s (CLYM) Stock Is Down 8.94%
As of Friday, October 16, Climb Bio, Inc.’s CLYM share price has dipped by 8.94%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Climb Bio, Inc.’s (CLYM) Stock Is Up 5.93%
As of Thursday, October 15, Climb Bio, Inc.’s CLYM share price has surged by 5.93%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Climb Bio, Inc.’s (CLYM) Stock Is Up 5.83%
As of Thursday, October 15, Climb Bio, Inc.’s CLYM share price has surged by 5.83%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | CLYM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $564.0 | $208.8 | 39% |
|
| Shares Out (Mil) | 76.2 | 53.9 | 57% |
|
| Institutional Ownership | 97.9% | 93.1% | 76% |
|
| Float (Mil) | 38.7 | 41.4 | 41% |
|
| Beta | 0.08 | 0.95 | 8% |
|
| Avg Daily Volume (000s) | 901 | 614 | 68% |
|
| Price Change (52-week) |
406.2% | 45.3% | 100% |
|
| Growth | CLYM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (23.7%) | (10.2%) | 17% |
|
| EPS (5yr) | 38.9% | 15.7% | 88 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (17.8%) | (15.7%) | 39% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.194) | ($0.776) | ($1.003) | |
| Month Ago EPS | ($0.194) | ($0.776) | ($1.003) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | ($0.211) | ($0.868) | ($1.122) | |
| Year/Year Chg | 9.6% | (13.5%) | 63.9% | |
| Financials | CLYM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($58) | ($44) | 15% |
|
| EPS (TTM) | ($0.835) | ($1.600) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($53) | ($33) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $755 | $174 | 38% |
|
| Valuation | CLYM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.35 | 2.09 | 60% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CLYM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (26.3%) | (47.2%) | 18% |
|
| ROE | (27.1%) | (54.2%) | 21% |
|
| Liabilities to Assets | 2.7% | 29.1% | 1% |
|
| F-Score | 2 | 2 | 7% |
|
Climb Bio, Inc. did not pass any screens on 10/16/2026.
